Patents
Literature
5 results about "CRISPR/Cpf1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 or CRISPR/Cpf1 is a DNA-editing technology analogous to the CRISPR/Cas9 system. Cpf1 is an RNA-guided endonuclease of a class II CRISPR/Cas system. This acquired immune mechanism is found in Prevotella and Francisella bacteria. It prevents genetic damage from viruses. Cpf1 genes are associated with the CRISPR locus, coding for an endonuclease that use a guide RNA to find and cleave viral DNA. Cpf1 is a smaller and simpler endonuclease than Cas9, overcoming some of the CRISPR/Cas9 system limitations. CRISPR/Cpf1 could have multiple applications, including treatment of genetic illnesses and degenerative conditions.
Compositions and methods for gene editing in T cells using CRISPR / CPF1
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
CRISPR / CPF1 Systems and Methods
This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR / Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR / Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
Owner:INTEGRATED DNA TECHNOLOGIES INC
Multi-pathway optimization method and strain for increasing N-acetylglucosamine production
The present invention discloses a method and strain for optimizing the production of N-acetylglucosamine using multiple pathways. The present invention is based on Bacillus subtilis 168 strain, and uses a genome editing system based on CRISPR / Cpf1 to construct a synthetic strain of N-acetylglucosamine from scratch. The competitive pathway is optimized by a high-throughput combination of a period-type CRISPRi system based on a stable phase promoter and dCpf1, thereby obtaining a more efficient and stable N-acetylglucosamine synthetic strain. The gene knockout and promoter replacement of the recombinant Bacillus subtilis constructed by the present invention are both completed using a genome scarless editing system based on CRISPR / Cpf1, and no plasmid is used in the final strain. Therefore, glucose can be sustainably, stably and efficiently synthesized into acetylglucosamine, and its yield on a shake flask can reach 33.7g / L, laying the foundation for its industrialization.
Owner:JIANGNAN UNIV
CRISPR / Cpf1 systems and methods
This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR / Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR / Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
Owner:INTEGRATED DNA TECHNOLOGIES INC
